ライフサイエンスコーパス: overcome resistance to

1 d at restoring lysosomal functionality might overcome resistance to ADC-based therapies and improve t

2 To investigate therapeutic strategies to overcome resistance to anastrozole treatment, we have us

3 ells, which could be a promising strategy to overcome resistance to anti-EGFR therapy.

4 ted whether dual Ang-2/VEGF inhibition could overcome resistance to anti-VEGF treatment.

5 iangiogenesis drugs may be a new strategy to overcome resistance to antiangiogenesis therapy.

6 ultaneously may be an attractive strategy to overcome resistance to antiangiogenesis therapy.

7 xenografts suggests that inhibiting Dll4 may overcome resistance to antivascular endothelial growth f

8 poptosis; conversely, overexpression of XAF1 overcame resistance to apoptosis induction by IFN-beta.

9 antisense to DNA methyltransferase 1 (DNMT1) overcame resistance to apoptosis induction by IFNs with

10 geting growth factor receptors and pathways, overcoming resistance to apoptosis, and modifying epigen

11 with other agents have been investigated for overcoming resistance to AR-targeted therapies.

12 rt to find new pharmacological modalities to overcome resistance to ATP-binding-site inhibitors of Bc

13 s, we summarize small molecule strategies to overcome resistance to beta-lactam antibiotics.

14 as a new strategy to enhance sensitivity or overcome resistance to bortezomib.

15 eatment with the AR inhibitor, enzalutamide, overcame resistance to cabazitaxel.

16 Overcoming resistance to chemotherapy is an area that ne

17 4, whose overexpressions are correlated with overcoming resistance to cisplatin therapy, were also id

18 To overcome resistance to conventional anti-androgens of hu

19 riggers caspase-dependent apoptosis, and can overcome resistance to conventional therapeutics (i.e.,

20 Because of its potency, hCPT might overcome resistance to CPT in some cancer cells.

21 ce they synergize Cry toxins and are able to overcome resistance to Cry toxins.

22 g new targets for combination therapies that overcome resistance to current treatments and promote lo

23 in the development of strategies designed to overcome resistance to currently available TKIs.

24 In models of multiple myeloma, CpdA overcame resistance to dexamethasone, doxorubicin, and m

25 tiveness of existing cancer therapies and to overcome resistance to drugs such as BRAF inhibitors (BR

26 Therefore, a combination strategy to overcome resistance to EGFR mono-targeted therapy is cli

27 epresents a novel pharmacologic strategy for overcoming resistance to EGFR inhibitors in patients wit

28 llosteric and ATP-competitive inhibitors can overcome resistance to either agent alone.

29 l 3-kinase (PI3K) is a promising approach to overcome resistance to endocrine therapy in breast cance

30 ylase inhibitors (HDACis) have been shown to overcome resistance to epidermal growth factor receptor

31 cent approval of third-generation therapies, overcoming resistance to epidermal growth factor recepto

32 This finding has clear implications for overcoming resistance to erlotinib.

33 pment of a new class of mTOR inhibitors that overcomes resistance to existing first- and second-gener

34 Overcoming resistance to Fas in asmase(-/-) hepatocytes

35 gents, and (3) development of molecules that overcome resistance to FLT3 inhibitors that arise as a r

36 akthrough, leading to complete remission and overcoming resistance to FLT3 inhibitors.

37 HER2+ breast cancers in order to prevent or overcome resistance to HER2 inhibitors.

38 essment of PI3K inhibition as an approach to overcome resistance to hormonal therapy, inhibitors with

39 ule PI3Kgamma inhibitor, such as IPI-549, to overcome resistance to ICB in patients with high levels

40 iple effective agents are being developed to overcome resistance to imatinib.

41 increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy.

42 MET-targeted agents in coculture systems and overcame resistance to JNJ-38877605, crizotinib, and DN3

43 of tumor cell lines to provide a strategy to overcome resistance to kinase inhibitor therapy.

44 was active in Rh41-MAB391R cells and able to overcome resistance to MAB391, but MAB391 was not active

45 we validated a drug combination predicted to overcome resistance to MEK inhibitors by coblockade of G

46 Our findings suggest novel approaches to overcome resistance to MEK inhibitors by combining AZD62

47 o further enhance the antitumor activity and overcome resistance to MTPA-induced apoptosis in cancer

48 n-responsive hypothalamic neurons, partially overcomes resistance to obesity in PTP1B(-/-) mice.

49 Carfilzomib also overcame resistance to other conventional agents and act

50 function, induces apoptosis in MM cells and overcomes resistance to proteasome inhibitor bortezomib.

51 rials of SCIO-469 to enhance sensitivity and overcome resistance to PS-341, thereby improving patient

52 efore determined whether CT-32615 could also overcome resistance to PS-341.

53 Moreover, proteasome inhibitors overcome resistance to quizartinib induced by mutations

54 evealing a potential therapeutic strategy to overcome resistance to RAF inhibition in a subset of BRA

55 rate that concomitant inhibition of IAPs can overcome resistance to RTK inhibitors in human malignant

56 n donor leukocyte infusions is important for overcoming resistance to second-set rejection induced by

57 th vital mitochondrial functions may help to overcome resistance to standard cancer therapy.

58 Overcoming resistance to taking opioids; initiating, tit

59 nstream point of vulnerability to prevent or overcome resistance to targeted drugs.

60 e metabolism may enhance the efficacy of and overcome resistance to targeted molecular cancer therapi

61 optotic machinery to improve sensitivity and overcome resistance to the therapies that target oncogen

62 ovide a potent novel therapeutic approach to overcome resistance to therapies and thereby improve pat

63 t be developed to inhibit CRC metastasis and overcome resistance to therapy associated with hypoxia.

64 d reveal new targets for drug development to overcome resistance to therapy.

65 ase (PI3K)/Akt/mTOR in WM, and mechanisms of overcoming resistance to therapy.

66 Targeting TIM-1 provides an approach to overcome resistance to tolerance in clinical transplanta

67 ed to the development of novel strategies to overcome resistance to tolerance.

68 selenium-based dietary compounds may help to overcome resistance to TRAIL-mediated apoptosis in prost

69 tochondria constitute an important target in overcoming resistance to TRAIL in many types of tumors.

70 he receptors for NRG1 and HGF, respectively, overcome resistance to trametinib provided by these grow

71 tumor bulk, suggesting potential regimens to overcome resistance to treatments and eradicate HNSCC me